Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Perfusion
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ohri, S. K
Right arrow Articles by Taylor, K. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohri, S. K
Right arrow Articles by Taylor, K. M
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A genetically engineered human Kunitz protease inhibitor with increased kallikrein inhibition in an ovine model of cardiopulmonary bypass

Sunil K Ohri

Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Imperial College School of Medicine, London

Rachel Parratt

Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Imperial College School of Medicine, London

Tyler White

Scios Inc, Sunnyvale, California

Jenny Becket

Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Imperial College School of Medicine, London

John J Brannan

Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Imperial College School of Medicine, London

Beverley J Hunt

Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Imperial College School of Medicine, London, Beverley.hunt{at}gstt.sthames.nhs.uk

Kenneth M Taylor

Department of Cardiothoracic Surgery, National Heart and Lung Institute, The Imperial College School of Medicine, London

A recombinant human serine protease inhibitor known as Kunitz protease inhibitor (KPI) wild type has functional similarities to the bovine Kunitz inhibitor, aprotinin, and had shown a potential to reduce bleeding in an ovine model of cardiopulmonary bypass (CPB). The aim of this study was to assess KPI-185, a modification of KPI-wild type that differs from KPI-wild type in two amino acid residues and which enhances anti-kallikrein activity in a further double-blind, randomized study in an ovine model of CPB, and to compare with our previous study of KPI-wild type and aprotinin in the same ovine model. Post-operative drain losses and subjective assessment of wound ‘dryness’ showed no significant differences between KPI-185 and KPI-wild type, despite the significant enhancement of kallikrein inhibition using KPI-185 seen in serial kallikrein inhibition assays.

These preliminary findings support the hypothesis that kallikrein inhibition is not the major mechanism by which Kunitz inhibitors such as aprotinin reduce perioperative bleeding.

Perfusion, Vol. 16, No. 3, 199-206 (2001)
DOI: 10.1177/026765910101600305
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?